FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 565 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities March 6, 2026 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Brain... September 30, 2021 Foodie Fridays-Gazpacho: A Favorite Summer Soup August 6, 2021 Steroids May Limit the Effectiveness of Immunotherapy for Brain Cancer December 28, 2020 Load more HOT NEWS New on NCI’s Websites for March 2023 FDA Grants Accelerated Approval to Zanubrutinib for Relapsed or Refractory Follicular... FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer Latest Data Indicate New Care Standard in Advanced/Recurrent Endometrial Cancer: Results...
